Related Experiment Video

Updated: Jul 11, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Novel cardiac myosin activators for acute heart failure

Thanjavur K M Bragadeesh1, Gaurav Mathur, Andrew L Clark

  • 1Castle Hill Hospital, Department of Academic Cardiology, Cottingham, Kingston-Upon-Hull, HU16 5JQ, UK. bragadeesh02@gmail.com

Expert Opinion on Investigational Drugs
|October 10, 2007
PubMed

Insights

Novel cardiac-specific myosin ATPase activators offer a new approach to treating heart failure by enhancing myocardial contractility. These agents represent a promising therapeutic strategy for improving outcomes in patients with heart failure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Heart failure is a major cause of mortality and hospitalization.
  • Acute heart failure treatments lag behind chronic heart failure therapies.
  • Current inotropic agents include catecholamines, phosphodiesterase inhibitors, and calcium sensitizers.

Purpose of the Study:

  • To review the mechanism of action of cardiac-specific myosin ATPase activators.
  • To summarize preclinical and Phase I study results.
  • To explore the potential role of these novel agents in heart failure management.

Main Methods:

  • Review of existing literature on myosin ATPase activators.
  • Analysis of preclinical data on efficacy and safety.
  • Examination of Phase I clinical trial outcomes.

Main Results:

  • Myosin ATPase activators enhance myocardial contractility by targeting the crossbridge cycle.
  • Preclinical studies demonstrate potential therapeutic benefits.
  • Phase I studies assess safety and tolerability in humans.

Conclusions:

  • Cardiac-specific myosin ATPase activators represent a novel class of inotropic agents.
  • These activators have a unique mechanism of action distinct from existing therapies.
  • Further research and clinical trials are warranted to establish their role in heart failure treatment.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.